Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

FHS
June 16, 2023
4:24 am

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

Meet the contenders for the STAT Madness 2024 crown. Voting begins March 1

The 64 contestants whose discoveries and innovations have been selected for the 2024 edition of STAT Madness come from 50 institutions across the U.S. The

February 28, 2024

Disability rights activist pushes government to let him participate in society

Garret Frey refuses to be sidelined. Frey has been paralyzed from the neck down for more than 37 of his 42 years. He has spent

August 23, 2024

JPM Day 3 had a cautiously optimistic outlook

In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.